Table 3. Univariate analysis demonstrating factors associated with OS and PFS.
| Factor | No. | OS p-value | PFS p-value |
| Sex | 0.149 | 0.774 | |
| Male | 89 | ||
| Female | 39 | ||
| Age (years) | 0.865 | 0.103 | |
| > 72 | 57 | ||
| ≤ 72 | 71 | ||
| Charlson score | 0.947 | 0.314 | |
| ≥ 1 | 42 | ||
| < 1 | 86 | ||
| Pathological grade | 0.847 | 0.683 | |
| Well differentiated | 10 | ||
| Moderately differentiated | 47 | ||
| Poorly/undifferentiated | 45 | ||
| Unknown | 26 | ||
| Location | 0.325 | 0.634 | |
| Upper third | 38 | ||
| Middle third | 69 | ||
| Lower third | 21 | ||
| Primary tumor length | 0.039 | 0.169 | |
| ≤ 5 cm | 78 | ||
| > 5 cm | 50 | ||
| T stage | 0.000 | 0.007 | |
| T1-T2 | 25 | ||
| T3-T4 | 103 | ||
| N stage | 0.804 | 0.359 | |
| N0 | 26 | ||
| N1 | 102 | ||
| M stage | 0.012 | 0.041 | |
| M0 | 78 | ||
| M1 | 50 | ||
| Radiation dose (Gy) | 0.056 | 0.226 | |
| < 60 | 49 | ||
| ≥ 60 | 79 | ||
| Treatment modality | 0.008 | 0.004 | |
| CCRT | 73 | ||
| RT alone | 55 |
Abbreviations: OS, overall survival; PFS, progression-free survival; CCRT, concurrent chemoradiotherapy; RT, radiotherapy.